# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnolog...
- SEC Filing
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigationPrevious re...
In the study, complication-free survival revealed a 57% difference in favor of PrimeC over placebo after 12 months of treatment...
https://patentcenter.uspto.gov/applications/18047289/ifw/docs
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimat...